Wedbush reissued their outperform rating on shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) in a research report released on Thursday morning.

Other research analysts also recently issued reports about the stock. Zacks Investment Research downgraded shares of Lexicon Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, July 5th. Cowen and Company reissued a hold rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, August 1st. Needham & Company LLC reissued a buy rating and issued a $21.00 target price on shares of Lexicon Pharmaceuticals in a research report on Sunday, September 17th. BidaskClub downgraded shares of Lexicon Pharmaceuticals from a sell rating to a strong sell rating in a research report on Thursday, August 10th. Finally, ValuEngine raised shares of Lexicon Pharmaceuticals from a sell rating to a hold rating in a research report on Thursday, June 15th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of $28.75.

Lexicon Pharmaceuticals (NASDAQ:LXRX) opened at 11.74 on Thursday. The stock’s market cap is $1.24 billion. The company’s 50 day moving average is $13.38 and its 200 day moving average is $14.96. Lexicon Pharmaceuticals has a 52 week low of $11.62 and a 52 week high of $19.50.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.12. The business had revenue of $12.00 million for the quarter, compared to the consensus estimate of $18.34 million. Lexicon Pharmaceuticals had a negative net margin of 170.63% and a negative return on equity of 94.87%. The firm’s quarterly revenue was down 40.3% compared to the same quarter last year. During the same period last year, the firm posted ($0.37) earnings per share. Equities analysts predict that Lexicon Pharmaceuticals will post ($1.47) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.thecerbatgem.com/2017/10/09/lexicon-pharmaceuticals-inc-lxrx-given-outperform-rating-at-wedbush.html.

In related news, insider Lonnel Coats purchased 30,000 shares of the firm’s stock in a transaction that occurred on Friday, September 15th. The stock was acquired at an average cost of $12.54 per share, for a total transaction of $376,200.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 5.77% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. State of Wisconsin Investment Board acquired a new stake in shares of Lexicon Pharmaceuticals during the second quarter worth approximately $510,000. Highbridge Capital Management LLC acquired a new stake in shares of Lexicon Pharmaceuticals during the first quarter worth approximately $7,813,000. Pictet Asset Management Ltd. boosted its holdings in shares of Lexicon Pharmaceuticals by 10.4% during the second quarter. Pictet Asset Management Ltd. now owns 67,950 shares of the biopharmaceutical company’s stock worth $941,000 after purchasing an additional 6,400 shares during the period. First Mercantile Trust Co. boosted its holdings in shares of Lexicon Pharmaceuticals by 11.2% during the second quarter. First Mercantile Trust Co. now owns 12,212 shares of the biopharmaceutical company’s stock worth $201,000 after purchasing an additional 1,227 shares during the period. Finally, Wellington Management Group LLP boosted its holdings in shares of Lexicon Pharmaceuticals by 11.1% during the first quarter. Wellington Management Group LLP now owns 279,874 shares of the biopharmaceutical company’s stock worth $4,013,000 after purchasing an additional 27,964 shares during the period.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Stock Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.